Healis Therapeutics has entered into a supply agreement with CKD Bio Corporation, a subsidiary of Chong Kun Dang group, for CKDB-501, a neuromodulator BoNT/A protein. Healis Therapeutics intends to develop CKDB-501 for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). In addition, Healis plans to enter clinical trials in the U.S. and other countries. According to Healis, ten randomized controlled trials conducted in five countries to date have shown promising early...